

2009

## Mutation I810N in the $\alpha 3$ isoform of Na<sup>+</sup>,K<sup>+</sup>-ATPase causes impairments in the sodium pump and hyperexcitability in the CNS

Steven J. Clapcote

Steven Duffy

Gang Xie

Greer Kirshenbaum

Allison R. Bechard  
*SUNY Geneseo*

*See next page for additional authors*

Follow this and additional works at: <https://knightscholar.geneseo.edu/psychology-faculty>

---

### Recommended Citation

Clapcote S.J., Duffy S., Xie G., Kirshenbaum G., Bechard A.R., Schack V.R., Petersen J., Sinai L., Saab B.J., Lerch J.P., Minassian B.A., Ackerley C.A., Sled J.G., Cortez M.A., Henderson J.T., Vilsen B., Roder J.C. (2009). Proceedings of the National Academy of Sciences of the United States of America, 106, 14085-14090 doi: 10.1073/pnas.0904817106

This Article is brought to you for free and open access by the By Department at KnightScholar. It has been accepted for inclusion in Psychology faculty/staff works by an authorized administrator of KnightScholar. For more information, please contact [KnightScholar@geneseo.edu](mailto:KnightScholar@geneseo.edu).

---

## Authors

Steven J. Clapcote, Steven Duffy, Gang Xie, Greer Kirshenbaum, Allison R. Bechard, Vivien Rodacker Schack, Janne Petersen, Laleh Sinai, Bechara J. Saab, Jason P. Lerch, Berge A. Minassian, Cameron A. Ackerley, John G. Sled, Miguel A. Cortez, Jeffrey T. Henderson, Bente Vilsen, and John C. Roder

# Mutation I810N in the $\alpha 3$ isoform of $\text{Na}^+, \text{K}^+$ -ATPase causes impairments in the sodium pump and hyperexcitability in the CNS

Steven J. Clapcote<sup>a,b,1</sup>, Steven Duffy<sup>a</sup>, Gang Xie<sup>a</sup>, Greer Kirshenbaum<sup>a,c</sup>, Allison R. Bechard<sup>a</sup>, Vivien Rodacker Schack<sup>d</sup>, Janne Petersen<sup>d</sup>, Laleh Sinai<sup>a,c</sup>, Bechara J. Saab<sup>a,c</sup>, Jason P. Lerche<sup>e</sup>, Berge A. Minassian<sup>c,e</sup>, Cameron A. Ackerley<sup>e</sup>, John G. Sled<sup>c,e</sup>, Miguel A. Cortez<sup>c,e</sup>, Jeffrey T. Henderson<sup>c</sup>, Bente Vilsen<sup>d</sup>, and John C. Roder<sup>a,c</sup>

<sup>a</sup>Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada M5G 1X5; <sup>b</sup>Institute of Membrane and Systems Biology, University of Leeds, Leeds LS2 9JT, United Kingdom; <sup>c</sup>Departments of Medical Biophysics, Medical Genetics, Paediatrics, and Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada M5S 1A1; <sup>d</sup>Department of Physiology and Biophysics, Centre for Membrane Pumps in Cells and Disease—PUMPKIN, Danish National Research Foundation, University of Aarhus, DK-8000 Aarhus, Denmark; and <sup>e</sup>Mouse Imaging Centre, Program in Genetics and Genome Biology, and Divisions of Neurology and Pathology, Hospital for Sick Children, Toronto, ON, Canada M5G 1X8

Edited by Ernest Marshal Wright, University of California, Los Angeles, CA, and accepted by the Editorial Board June 9, 2009 (received for review May 1, 2009)

**In a mouse mutagenesis screen, we isolated a mutant, *Myshkin* (*Myk*), with autosomal dominant complex partial and secondarily generalized seizures, a greatly reduced threshold for hippocampal seizures *in vitro*, posttetanic hyperexcitability of the CA3-CA1 hippocampal pathway, and neuronal degeneration in the hippocampus. Positional cloning and functional analysis revealed that *Myk/+* mice carry a mutation (I810N) which renders the normally expressed  $\text{Na}^+, \text{K}^+$ -ATPase  $\alpha 3$  isoform inactive. Total  $\text{Na}^+, \text{K}^+$ -ATPase activity was reduced by 42% in *Myk/+* brain. The epilepsy in *Myk/+* mice and *in vitro* hyperexcitability could be prevented by delivery of additional copies of wild-type  $\text{Na}^+, \text{K}^+$ -ATPase  $\alpha 3$  by transgenesis, which also rescued  $\text{Na}^+, \text{K}^+$ -ATPase activity. Our findings reveal the functional significance of the  $\text{Na}^+, \text{K}^+$ -ATPase  $\alpha 3$  isoform in the control of epileptiform activity and seizure behavior.**

$\alpha 3$   $\text{Na}^+, \text{K}^+$  ATPase | BAC rescue | epilepsy | forward genetic screen | mouse

**E**pilepsy is a debilitating neurological disorder characterized by recurrent seizures triggered by excessive neuronal excitability in the brain. At least 40–50% of all forms of epilepsy are idiopathic, and thus have a presumed genetic origin (1). Identifying genetic and pathophysiological pathways involved in epilepsy is critical for the rational design of improved treatments for the one-third of epilepsy patients who do not respond to current medications (2).

$\text{Na}^+, \text{K}^+$ -ATPases (sodium/potassium pumps) play a seminal role in controlling neuronal excitability by maintaining electrochemical gradients for  $\text{Na}^+$  and  $\text{K}^+$  across the plasma membrane. Hence, it has been hypothesized that an abnormality in  $\text{Na}^+, \text{K}^+$ -ATPase could facilitate seizures (3–6). Indeed, partial inhibition of  $\text{Na}^+, \text{K}^+$ -ATPase activity with cardiac glycosides has been shown to induce seizures in rats (7–9). Furthermore, some patients with the autosomal dominant genetic disorder familial hemiplegic migraine (FHM) type 2, caused by mutation of the  $\text{Na}^+, \text{K}^+$ -ATPase  $\alpha 2$ -isoform, have a clinical history of epileptic seizures (10). Three isoforms of the  $\text{Na}^+, \text{K}^+$ -ATPase  $\alpha$ -subunit,  $\alpha 1$ ,  $\alpha 2$ , and  $\alpha 3$ , encoded by paralogous genes (*Atp1a1*, *Atp1a2*, and *Atp1a3*, respectively), are expressed in mammalian brain:  $\alpha 1$  as the housekeeping enzyme in a variety of cell types,  $\alpha 2$  predominantly in glial cells in human adults, and  $\alpha 3$  exclusively in neurons (11). The increased epileptic propensity observed in patients with FHM, and thus the role of the  $\text{Na}^+, \text{K}^+$ -ATPase  $\alpha 2$ -isoform in generation of seizures, has been explained by the reduced ability of glial cells to clear the extracellular space of  $\text{K}^+$  and glutamate (6). So far there has been no convincing evidence linking the neuron specific  $\alpha 3$ -isoform of  $\text{Na}^+, \text{K}^+$ -ATPase to epilepsy. Mutations in the human *ATP1A3* gene encoding  $\alpha 3$  are associated with rapid-onset dystonia-parkinsonism (RDP), but seizures are not a typical characteristic of this disease (12)—possibly because most known RDP mutations are compatible with partial NKA function

(13). The similar affinities of  $\alpha 2$  and  $\alpha 3$  for the  $\text{Na}^+, \text{K}^+$ -ATPase inhibitor ouabain have precluded conclusive pharmacological studies of isoform specificity.

Here, we present a mouse model for epilepsy caused by mutation of the  $\text{Na}^+, \text{K}^+$ -ATPase  $\alpha 3$ -isoform. We have used *in vivo* mutagenesis with N-nitroso-N-ethylurea (ENU) (14) to generate a mutant named *Myshkin* (*Myk*) that displays seizures and neuronal hyperexcitability in heterozygotes (*Myk/+*) and perinatal death in homozygotes (*Myk/Myk*). The *Myshkin* allele contains a point mutation in the  $\text{Na}^+, \text{K}^+$ -ATPase  $\alpha 3$ -isoform that inactivates this enzyme and is solely responsible for complex partial and secondarily generalized seizures in these mice.

## Results and Discussion

In a screen for dominant visible phenotypes among 8-week-old progeny of ENU mutagenized 129S1/SvImJ (129S1) males and untreated C57BL/6J females, we found a female with a small body. This phenotype proved to be heritable as a Mendelian autosomal dominant trait, as 10 of 23 (43.5%) N2 progeny of this mouse and a C57BL/6Ncr (B6) male had a visibly smaller body than their same-sex littermates (see Fig. S1). We observed that the small mice exhibited spontaneous, recurrent convulsive seizures in the home cage from weaning at 4 weeks of age. When bred to homozygosity, *Myk/Myk* pups appeared grossly normal but died shortly after birth, indicating that the seizure and small body phenotype of *Myk/+* mice is semidominant. We localized the *Myshkin* allele to a nonrecombinant interval of chromosome 7 (Fig. 1). Sequencing of genomic DNA and whole brain cDNA from *Myk/Myk* ( $n = 2$ ), *Myk/+* ( $n = 2$ ), and  $+/+$  ( $n = 2$ ) mice revealed 2 *de novo* mutations in the *Atp1a3* gene encoding the  $\alpha 3$  isoform of the  $\text{Na}^+, \text{K}^+$ -ATPase, predicted to result in amino acid substitutions Asp<sup>65</sup>→Glu (D65E) and Ile<sup>810</sup>→Asn (I810N) (Fig. 1). Each of these amino acids is conserved across vertebrate species (Fig. 1). Both mutations appeared in 107 *Myk/+* mice after 12 generations of backcrossing to B6, but neither was found in 104  $+/+$  littermates. Hence, *Myshkin* is an allele of *Atp1a3* (*Atp1a3*<sup>*Myk*</sup>).

Author contributions: J.C.R. designed research; S.J.C., S.D., G.X., G.K., A.R.B., V.R.S., J.P., L.S., B.J.S., J.P.L., B.A.M., C.A.A., J.G.S., M.A.C., J.T.H., and B.V. performed research; S.J.C., S.D., G.K., A.R.B., V.R.S., J.P., L.S., B.J.S., J.P.L., B.A.M., C.A.A., J.G.S., M.A.C., J.T.H., B.V., and J.C.R. analyzed data; and S.J.C., S.D., B.V., and J.C.R. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission. E.M.W. is a guest editor invited by the Editorial Board.


<sup>1</sup>To whom correspondence should be addressed at: Institute of Membrane and Systems Biology, Garstang Building, University of Leeds, Leeds LS2 9JT, United Kingdom. E-mail: s.j.clapcote@leeds.ac.uk.

This article contains supporting information online at [www.pnas.org/cgi/content/full/0904817106/DCSupplemental](http://www.pnas.org/cgi/content/full/0904817106/DCSupplemental).









**Fig. 5.** Mutational and BAC transgenesis effects on Na<sup>+</sup>,K<sup>+</sup>-ATPase activity and  $\alpha$ 3 expression in brain. (A) Specific Na<sup>+</sup>,K<sup>+</sup>-ATPase activity in brain homogenates of 10-week-old *Myk1+* ( $n = 6$ ) and *tm1Ling1+* mice ( $n = 4$ ) and of *Myk1+* ( $n = 11$ ) and *Myk1/Myk* E18 fetuses ( $n = 5$ ) (mean  $\pm$  SEM). Results are expressed as a % of +/+ littermate levels (adults  $n = 6$ , fetuses  $n = 7$ ). \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ; \*\*\*\*,  $P < 0.0001$  versus respective +/+ littermates; ####  $P < 0.001$  versus *tm1Ling1+* mice. (B) Specific Na<sup>+</sup>,K<sup>+</sup>-ATPase activity in brain homogenates of 10-week-old *Myk1+* ( $n = 4$ ) and *Myk1+/BAC* ( $n = 4$ ) mice (mean  $\pm$  SEM). Results are expressed as a % of +/+ littermate levels. \*\*,  $P < 0.01$  versus *Myk1+* mice; ####  $P < 0.0001$  versus +/+ mice. (C) Typical blots of 20  $\mu$ g protein from brains probed with anti-Na<sup>+</sup>,K<sup>+</sup>-ATPase  $\alpha$ 3, anti-NR1, and anti- $\beta$ -tubulin III antibodies (Left). Immunoreactivity of *Myk1/Myk* ( $n = 4$ ) and *Myk1+* ( $n = 6$ ) E18 fetus brains and *Myk1+* ( $n = 8$ ) adult brains expressed as a percentage of +/+ (E18  $n = 4$ ; adult  $n = 8$ ) levels (Right). Each sample was blotted 3 times, and  $\beta$ -tubulin III was used as loading control. \*,  $P < 0.05$  versus +/+ E18 fetus brains (Right). (D) Distribution and signal intensity of  $\alpha$ 3 (Red) and agrin (Green) in cultured neocortical neurons from E18 fetuses (Left). (Scale bar, 24  $\mu$ m.) Colocalization coefficients for *Myk1/Myk* ( $n = 14$ ) and +/+ ( $n = 14$ ) E18 fetuses (Right).

control of epileptogenesis and seizure behavior. Given the high level of homology between the different Na<sup>+</sup>,K<sup>+</sup>-ATPase isoforms of mice and humans, our findings suggest that inactivating mutation of *ATPLA3* is a candidate mechanism for human epilepsy, and highlight  $\alpha$ 3 and its physiological regulators as putative targets for the rational design of antiepileptic therapies.

## Materials and Methods

**Mice.** Animal procedures were approved by the Animal Management Committee of Mount Sinai Hospital and were conducted in accordance with the requirements of the Ontario Animals for Research Act 1971 and the Canadian Council on Animal Care. We backcrossed *Myk1+* mice to the C57BL/6NCR strain (National Cancer Institute) for 12 generations before conducting phenotypic tests on sex-balanced groups of *Myk1+* and +/+ N12 littermates at 10–14 weeks of age. PCR-based genotyping assays for each mouse line are described in the *SI Text*.

**Linkage Mapping and Positional Cloning.** The meiotic linkage mapping and positional cloning strategy that we used to identify the *Myshkin* mutation has been described previously (14).

**Na<sup>+</sup>,K<sup>+</sup>-ATPase Mutants Expressed in COS Cells.** Using the QuikChange Site-Directed Mutagenesis kit (Stratagene), mutations D65E, I810N, and the combination D65E+I810N were introduced directly into full-length cDNA encoding an ouabain resistant version of the human  $\alpha$ 3 isoform, which carried the mutations Q108R and N119D to reduce the affinity for ouabain (27). To examine the functionality of the mutant and wild-type ouabain resistant enzymes, the cDNAs inserted in the expression vector pCMV6-XL-5 were transfected into COS-1 cells grown in the presence of 5  $\mu$ M ouabain, which preferentially inhibits the ouabain-sensitive Na<sup>+</sup>,K<sup>+</sup>-ATPase endogenously present in COS-1 cells (15).

**Electrocorticography.** Stereotactic implantation of electrodes and ECoG recordings were carried out on *Myk1+*, *Myk1+/BAC*, and +/+ mice, as described previously (28).

**Valproic Acid Treatment and Seizure Scoring.** From weaning at 4 weeks of age, *Myk1+* mice were i.p. injected daily for 66 days with either sodium valproate (150 mg/kg; Sigma) dissolved in distilled water ( $n = 13$ ) or vehicle ( $n = 10$ ) in a volume of 10 mL/kg body weight. The dose was determined by reference to a previous study of C57BL/6 mice (29). Mice were placed in a clean cage 30 min after the last injection. After a habituation period of 5 min, the cage was shaken for 30 s and seizure behavior was observed for 2 min. Seizure behavior was quantified on a 1–6 scale using the following behavioral scoring system: 1, running; 2, staring; 3, tail raise/vibrating; 4, small myoclonic jerk; 5, large myoclonic jerk (raising mouse into the air); 6, tonic-clonic seizure. The score assigned reflected the highest grade seizure behavior expressed by the mouse within the test.

**BAC Transgenic Mice.** MSMg01–344N17 BAC DNA of *Mus musculus molossinus* origin was purified in a NucleoBond AX500 column (Machery-Nagel) and resuspended in polyamine microinjection buffer. BAC DNA was injected into the pronucleus of (C57BL/6  $\times$  SJL) F2 embryos, which were then transferred into the oviducts of 0.5 day pseudopregnant CD-1 females (Charles River Laboratories). From among the 154 pups born, 6 BAC transgenic pups were identified by PCR amplification across the SP6 and T7 vector-insert boundaries and by the presence of a *Bse*YI (New England Biolabs) restriction site (ss60981659; 5'-C\*CCAGC-3'). Germline transmission and good breeding performance were established in 1 line.

**In Vitro Electrophysiology.** *Myk1+* and +/+ mice (14–16 weeks old) were decapitated under isoflurane anesthesia and their brains isolated in ice-cold artificial cerebrospinal fluid (aCSF) containing (in mM): 124 NaCl, 26 NaHCO<sub>3</sub>,

3 KCl, 2 CaCl<sub>2</sub>, 2 MgCl<sub>2</sub>, 26 NaHCO<sub>3</sub>, 1.2 NaH<sub>2</sub>PO<sub>4</sub>, and 10 glucose. For experiments employing hippocampal slices, whole hippocampi were isolated, sliced at 400  $\mu$ m on a manual chopper (Stoelting), and maintained as described previously (30). Methods for studies of in vitro epilepsy are described in the *SI Text*.

**Magnetic Resonance Imaging.** Magnetic resonance imaging was conducted as described previously (31).

**Electron Microscopy.** Electron microscopy was conducted as described previously (32).

**Na<sup>+</sup>,K<sup>+</sup>-ATPase Functional Assays of Brain Homogenates.** Brain tissue was homogenized in a buffer containing 85 mM NaCl, 20 mM KCl, 4 mM MgCl<sub>2</sub>, 0.2 mM EGTA, 30 mM histidine (pH 7.2), and 10% sucrose (wt/vol), and was further permeabilized by incubation with 0.65 mg sodium deoxycholate/mL at a total brain protein concentration of 0.3 mg/mL in the presence of 2 mM EDTA and 2 mM imidazole at 20°C. The ouabain sensitive Na<sup>+</sup>- and K<sup>+</sup>-activated ATP hydrolysis rate was determined at 37°C by a colorimetric assay for liberated P<sub>i</sub> (15). The deoxycholate treated brain tissue homogenate (25  $\mu$ L) was added to 500  $\mu$ L ATPase buffer containing 30 mM histidine (pH 7.5), 140 mM NaCl, 20 mM KCl, 3 mM MgCl<sub>2</sub>, and 1 mM EGTA, and was allowed to react for 5 min with 3 mM ATP in the presence and absence of 3 mM ouabain. When the Na<sup>+</sup> concentration was varied, the K<sup>+</sup> concentration was kept at 20 mM, and when the K<sup>+</sup> concentration was varied, the Na<sup>+</sup> concentration was kept at 40 mM. The Na<sup>+</sup>,K<sup>+</sup>-ATPase active site concentration was determined by phosphorylation at 0°C in the presence of 2  $\mu$ M [ $\gamma$ -<sup>32</sup>P]ATP, 20 mM Tris (pH 7.5), 3 mM MgCl<sub>2</sub>, 150 mM NaCl, 1 mM EGTA, and oligomycin (20  $\mu$ g/mL) to inhibit dephosphorylation, and the catalytic turnover rate was calculated as the ratio between the ATPase activity and the active site concentration. In some experiments, the phosphorylation level was also determined at higher Mg<sup>2+</sup> concentrations but under otherwise similar conditions. The phosphoenzyme was quantified using the Packard Cyclone storage phosphor

system after acid quenching, washing by centrifugation and SDS-polyacrylamide gel electrophoresis at pH 6.0. The background phosphorylation determined in the presence of 50 mM KCl without NaCl was subtracted.

**Protein Extraction and Blot Analysis.** Whole brain homogenates from *Myk/Myk*, *Myk/+* and *+/+* E18 fetuses and from 12-week-old *Myk/+*, *+/+* and *Myk/+BAC* mice were subjected to SDS/PAGE followed by blotting and visualization with goat anti-Na<sup>+</sup>,K<sup>+</sup>-ATPase  $\alpha$ 3 (sc-16052; Santa Cruz; 1:100) or rabbit anti-NR1 (06–311; Upstate; 1:1,000). Immune complexes were detected by chemiluminescence (ECL Western blotting detection reagents, GE Healthcare). Plasma membrane and ER fractions of COS-1 cells transiently expressing transfected WT and mutant Na<sup>+</sup>,K<sup>+</sup>-ATPase were isolated by differential centrifugation according to procedures described previously (15, 33), and subjected to SDS/PAGE followed by blotting and visualization with anti-Na<sup>+</sup>,K<sup>+</sup>-ATPase  $\alpha$ 3 mouse monoclonal primary antibody (A-273; Sigma) and HRP-conjugated goat anti-mouse IgG secondary antibody.

**Immunocytochemistry.** Neocortical neuron cultures were prepared from E18 embryos, as described previously (34), and subjected to immunostaining with rabbit anti-Na<sup>+</sup>,K<sup>+</sup>-ATPase  $\alpha$ 3 (06–172; Upstate; 1:1,000) or mouse anti-agrin (AGR-131; Novus; 1:500) primary antibodies.

**ACKNOWLEDGMENTS.** We thank I. Vukobradovic, E. Weiss, J. Georgiou, and K. Lykke Pedersen for technical assistance; C. Snead and S. Cordes for advice; J. Lingrel for the provision of *Atp1a3<sup>tm1Lingl/+</sup>* mice; and P. Carlen for critical reading of the manuscript. This work was supported by grants-in-aid to J.C.R. from the Canadian Institutes of Health Research (MOP 94856), and to B.V. from the Lundbeck Foundation, the Novo Nordisk Foundation (Fabrikant Vilhelm Pedersen og Hustrus Legat), the Danish Medical Research Council, and the Danish National Research Foundation (PUMPKIN Centre). J.C.R. holds a Canada Research Chair. S.J.C. held a Postdoctoral Fellowship from the Royal Society of London. J.T.H., S.D. and S.J.C. held Young Investigator Awards from the National Alliance for Research on Schizophrenia and Depression. J.P.L. was supported by a Canadian Institutes of Health Research fellowship.

- Hauser WA, Hesdorffer DC (1990) *Epilepsy: Frequency, Causes and Consequences* (Demos Press, New York).
- Schmidt D, Löscher W (2005) Drug resistance in epilepsy: Putative neurobiologic and clinical mechanisms. *Epilepsia* 46:858–877.
- Grisar T, Guillaume D, Delgado-Escueta AV (1992) Contribution of Na<sup>+</sup>,K<sup>+</sup>-ATPase to focal epilepsy: A brief review. *Epilepsy Res* 12:141–149.
- Haglund MM, Schwartzkroin PA (1990) Role of Na-K pump potassium regulation and IPSPs in seizures and spreading depression in immature rabbit hippocampal slices. *J Neurophysiol* 63:225–239.
- Somjen GG (2002) Ion regulation in the brain: Implications for pathophysiology. *Neuroscientist* 8:254–267.
- Pietrobon D (2005) Migraine: New molecular mechanisms. *Neuroscientist* 11:373–386.
- Davidson DL, Tsukada Y, Barbeau A (1978) Ouabain induced seizures: Site of production and response to anticonvulsants. *Can J Neurol Sci* 5:405–411.
- Xiong ZQ, Stringer JL (2000) Sodium pump activity, not glial spatial buffering, clears potassium after epileptiform activity induced in the dentate gyrus. *J Neurophysiol* 83:1443–1451.
- Vaillend C, Mason SE, Cuttle MF, Alger BE (2002) Mechanisms of neuronal hyperexcitability caused by partial inhibition of Na<sup>+</sup>-K<sup>+</sup>-ATPases in the rat CA1 hippocampal region. *J Neurophysiol* 88:2963–2978.
- Gallanti A, et al. (2008) A novel de novo nonsense mutation in ATP1A2 associated with sporadic hemiplegic migraine and epileptic seizures. *J Neurol Sci* 273:123–126.
- McGrail KM, Phillips JM, Sweadner KJ (1991) Immunofluorescent localization of three Na,K-ATPase isozymes in the rat central nervous system: Both neurons and glia can express more than one Na,K-ATPase. *J Neurosci* 11:381–391.
- Brashear A, et al. (2007) The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. *Brain* 130:828–835.
- Rodacker V, Toustrup-Jensen M, Vilsen B (2006) Mutations Phe785Leu and Thr618Met in Na<sup>+</sup>,K<sup>+</sup>-ATPase, associated with familial rapid-onset dystonia parkinsonism, interfere with Na<sup>+</sup> interaction by distinct mechanisms. *J Biol Chem* 281:18539–18548.
- Snead OC, Clapcote SJ, Roder JC, Boulianne GL (2006) Novel strategies for the development of animal models of refractory epilepsy. *Adv Neurol* 97:155–171.
- Vilsen B (1992) Functional consequences of alteration to Pro<sup>328</sup> and Leu<sup>332</sup> located in the 4<sup>th</sup> transmembrane segment of the  $\alpha$ -subunit of the rat kidney Na<sup>+</sup>,K<sup>+</sup>-ATPase. *FEBS Lett* 314:301–307.
- Morth JP, et al. (2007) Crystal structure of the sodium-potassium pump. *Nature* 450:1043–1049.
- Avoli M, et al. (2002) Network and pharmacological mechanisms leading to epileptiform synchronization in the limbic system in vitro. *Prog Neurobiol* 68:167–207.
- Tancredi V, Hwa GG, Zona C, Brancati A, Avoli M (1990) Low magnesium epileptogenesis in the rat hippocampal slice: Electrophysiological and pharmacological features. *Brain Res* 511:280–290.
- McNamara JO, Huang YZ, Leonard AS (2006) Molecular signaling mechanisms underlying epileptogenesis. *Sci STKE* 356:12.
- Hilgenberg LG, Su H, Gu H, O'Dowd DK, Smith MA (2006)  $\alpha$ 3Na<sup>+</sup>,K<sup>+</sup>-ATPase is a neuronal receptor for agrin. *Cell* 125:359–369.
- Moseley AE, et al. (2007) Deficiency in Na,K-ATPase  $\alpha$  isoform genes alters spatial learning, motor activity, and anxiety in mice. *J Neurosci* 27:616–626.
- Misawa H, et al. (2002) Identification of a monogenic locus (*Jams1*) causing juvenile audiogenic seizures in mice. *J Neurosci* 22:10088–10093.
- Yang Y, Frankel WN (2004) Genetic approaches to studying mouse models of human seizure disorders. *Adv Exp Med Biol* 548:1–11.
- Ikeda K, et al. (2003) Degeneration of the amygdala/piriform cortex and enhanced fear/anxiety behaviors in sodium pump  $\alpha$ 2 subunit (*Atp1a2*)-deficient mice. *J Neurosci* 23:4667–4676.
- Wang J, et al. (2003) Interaction of calcineurin and type-A GABA receptor gamma 2 subunits produces long-term depression at CA1 inhibitory synapses. *J Neurosci* 23:826–836.
- Goodkin HP, Yeh JL, Kapur J (2005) Status epilepticus increases the intracellular accumulation of GABAA receptors. *J Neurosci* 25:5511–5520.
- Price EM, Lingrel JB (1988) Structure-function relationships in the Na,K-ATPase alpha subunit: Site-directed mutagenesis of glutamine-111 to arginine and asparagine-122 to aspartic acid generates a ouabain-resistant enzyme. *Biochemistry* 27:8400–8408.
- Cortez MA, McKerlie C, Snead OC (2001) A model of atypical absence seizures: EEG, pharmacology, and developmental characterization. *Neurology* 56:341–349.
- Ralph-Williams RJ, Paulus MP, Zhuang X, Hen R, Geyer MA (2003) Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. *Biol Psychiatry* 53:352–359.
- Duffy S, Labrie V, Roder JC (2008) D-serine augments NMDA-NR2B receptor-dependent hippocampal long-term depression and spatial reversal learning. *Neuropsychopharmacology* 33:1004–1018.
- Clapcote SJ, et al. (2007) Behavioral phenotypes of *Disc1* missense mutations in mice. *Neuron* 54:387–402.
- Wood DD, et al. (2008) Myelin localization of peptidylarginine deiminases 2 and 4: Comparison of PAD2 and PAD4 activities. *Lab Invest* 88:354–364.
- Maruyama K, MacLennan DH (1988) Mutation of aspartic acid-351, lysine-352, and lysine-515 alters the Ca<sup>2+</sup> transport activity of the Ca<sup>2+</sup>-ATPase expressed in COS-1 cells. *Proc Natl Acad Sci USA* 85:3314–3318.
- Liao D, Scannevin RH, Huganir R (2001) Activation of silent synapses by rapid activity-dependent synaptic recruitment of AMPA receptors. *J Neurosci* 21:6008–6017.